Nativel Collins
Family · Mantachie, MSNPI 1437162690
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $48,434 of the $72,995 with a category attached, or 66.4%. Novo Nordisk accounts for 79.6% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2021 at $37,466 and has fallen 97.5% since, to $935 in 2025. Among family clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 519 payments — averaging $140.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$58K
- AstraZeneca$9K
- Lilly USA, LLC$1K
- Medtronic$787
- Sanofi-aventis U.S. LLC$420
- Boehringer Ingelheim$407
- plus $3K from 23 others
What the payments were for
- Speaking & faculty fees$48,43466%
- Travel & lodging$15,27221%
- Food & beverage$9,22413%
- Education$650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 141 | $58,130 |
| AstraZeneca | 79 | $9,207 |
| Lilly USA, LLC | 68 | $1,079 |
| Medtronic | 29 | $787 |
| Sanofi-aventis U.S. LLC | 25 | $420 |
| Boehringer Ingelheim | 23 | $407 |
| Amgen | 19 | $332 |
| Xeris Pharmaceuticals, Inc. | 16 | $309 |
| Dexcom, Inc. | 15 | $259 |
| Amarin Pharma, Inc. | 15 | $239 |
| Bayer | 12 | $236 |
| Esperion Therapeutics, Inc. | 13 | $223 |
| Merck | 13 | $221 |
| Insulet Corporation | 6 | $220 |
| Abbott | 8 | $171 |
| BD | 7 | $171 |
| Sequel Med Tech, LLC | 7 | $135 |
| Corcept Therapeutics | 5 | $97 |
| Lifescan, Inc. | 3 | $63 |
| Rochester Medical Corporation | 2 | $49 |
| Pfizer | 2 | $46 |
| Novartis | 2 | $34 |
| Tandem Diabetes Care, Inc. | 2 | $33 |
| GRT US Holding, Inc. | 2 | $31 |
| Cequr Corporation | 1 | $21 |
| Vifor Pharma, Inc. | 1 | $20 |
| GSK | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$42,718
- Ozempic$12,156
- FARXIGA$8,037
- MINIMED 780G$266
- Omnipod$130
- BREZTRI$128
- Minimed 770G System$115
How this compares
$72,995 in reported general payments places this provider in the 95th percentile of 3,007 family providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 577 | $872,740 |
| MounjaroTirzepatide | 325 | $510,776 |
| JardianceEmpagliflozin | 175 | $196,805 |
| FarxigaDapagliflozin Propanediol | 208 | $191,688 |
| Tresiba Flextouch U-200Insulin Degludec | 93 | $129,527 |
| TrulicityDulaglutide | 83 | $119,535 |
| Tresiba Flextouch U-100Insulin Degludec | 121 | $112,908 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 82 | $107,196 |
| Xigduo XrDapaglifloz Propaned/Metformin | 87 | $90,655 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 54 | $54,853 |
| Novolog FlexpenInsulin Aspart | 153 | $53,861 |
| Humalog Kwikpen U-200Insulin Lispro | 17 | $49,325 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 38 | $40,999 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 48 | $38,423 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $38,043 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Novolog | $58,130 | $908,869627 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,079 | $630,311408 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $407 | $240,010215 claims |
| AstraZenecaFarxiga | $9,207 | $191,688208 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $420 | $16,79313 claims |
| MerckJanumet | $221 | $6,91912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,007 family providers in Mississippi.
Other family in Mantachie
- Dodie McGeeRaymond$772K
- Gina BurgeJackson$237K
- Christy DavisJackson$208K
- Maranda EversollFlowood$197K
- Dana DelaskiJackson$158K
- Kristin CarrollJackson$158K
- Shannon FryeryOxford$127K
- Ashley CocilovaFlowood$72K
- Andrea WallaceOlive Branch$50K
- Sarabeth HallBogue Chitto$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.